* IRadimed Corp IRMD.OQ IRMD.O is expected to show a fall in
quarterly revenue when it reports results on April 30.
* The Winter Springs, Florida-based company is expected to
report a 1.3% decrease in revenue to $8.562 million from $8.68
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for IRadimed Corp is for
earnings of 10 cents per share. For the same quarter last year,
the company reported earnings of 18 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for IRadimed Corp
is $29, about 8% above its last closing price of $26.67.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 0.11 0.11 0.07 Missed -33.3
Sep. 30 2020 0.10 0.10 0.11 Beat 10
Jun. 30 2020 0.00 0.00 0.05 Beat 1,100
Mar. 31 2020 0.12 0.15 0.18 Beat 20
Dec. 0.21 0.21 0.30 Beat 46.3
31 2019
Sep. 30 2019 0.16 0.16 0.23 Beat 48.4
Jun. 30 2019 0.15 0.15 0.20 Beat 33.3
Mar. 31 2019 0.17 0.15 0.13 Missed -13.3
This summary was machine generated April 28 at 12:59 GMT. All
figures in US dollars unless otherwise stated